Notification That Annual Report Will Be Submitted Late (nt 10-k)
April 01 2015 - 6:07AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
SEC
File Number: 001-13467
(Check
One): |
[X]
Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form
N-SAR [ ] Form N-CSR |
|
|
|
For Period Ended: December
31, 2014 |
|
|
|
[ ] Transition
Report on Form 10-K |
|
[ ] Transition
Report on Form 20-F |
|
[ ] Transition
Report on Form 11-K |
|
[ ] Transition
Report on Form 10-Q |
|
[ ] Transition
Report on Form N-SAR |
|
|
|
For the Transition
Period Ended: ________________ |
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification
relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
PART
I -- REGISTRANT INFORMATION
TARGETED
MEDICAL PHARMA, INC.
Full name
of registrant:
Former name
if applicable:
2980
Beverly Glen Circle, Suite 301
Address
of principal executive office (Street and number):
Los Angeles,
CA 90077
City, state
and zip code
PART
II -- RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate.)
|
(a) |
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
|
|
|
[X] |
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof,
will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition
report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and |
|
|
|
|
(c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III -- NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
Targeted
Medical Pharma, Inc. (the “Company”) was unable to file its Annual Report on Form 10-K for the fiscal year ended December
31, 2014 on a timely basis due to additional time needed for compilation and review to insure adequate disclosure of certain information
required to be included in the Form 10-K. The Company expects to file its Form 10-K within the additional time allowed by this
report.
PART
IV -- OTHER INFORMATION
(1) |
Name
and telephone number of person to contact in regard to this notification |
|
William
Horne |
|
(301) |
|
474-9809 |
|
(Name) |
|
(Area Code) |
|
(Telephone
Number) |
(2) |
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required
to file such report(s) been filed? If the answer is no, identify report(s). |
|
|
|
[X]
Yes [ ] No |
|
|
(3) |
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the subject report or portion thereof? |
|
|
|
[X]
Yes [ ] No |
|
|
|
If so, attach
an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made. |
|
|
|
Targeted
Medical Pharma, Inc. (the “Company”) anticipates that its revenue for the year ended December 31, 2014
will be approximately $7.1 million, significantly less than its revenue for the year ended December 31, 2013 of $9.6 million.
The decrease in revenue is primarily the result of a decrease in cash collections from the Company’s customers that are
accounted for pursuant to the cash method of accounting. The Company anticipates that its operating expenses for the year ended
December 31, 2014 will be significantly less than the year ended December 31, 2013 as a result of decreases in salary and general
and administrative expenses. The net loss before income taxes for the year ended December 31, 2014 is expected to be slightly
more than the year ended December 31, 2013 primarily as a result of these factors. |
Targeted
Medical Pharma, Inc.
(Name
of Registrant as Specified in Charter)
has caused
this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
March 31, 2015 |
Targeted
Medical Pharma, Inc. |
|
(Registrant) |
|
|
|
/s/ William
Horne |
|
William Horne |
|
Chief Financial
Officer |
ATTENTION
Intentional
misstatements or omissions of fact constitute Federal criminal violations. (See 18 U.S.C. 1001).
Targeted Medical Pharma (CE) (USOTC:TRGM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Targeted Medical Pharma (CE) (USOTC:TRGM)
Historical Stock Chart
From Aug 2023 to Aug 2024